

SS ISO 14971 : 2020
ISO 14971:2019, IDT
(ICS11.040.01)

SINGAPORE STANDARD

**Medical devices — Application of risk
management to medical devices**



SS ISO 14971 : 2020

ISO 14971:2019, IDT
(ICS 11.040.01)

SINGAPORE STANDARD

**Medical devices — Application of risk management
to medical devices**

Published by Enterprise Singapore

All rights reserved. Unless otherwise specified, no part of this Singapore Standard may be reproduced or utilised in any form or by any means, electronic or mechanical, including photocopying and microfilming, without permission in writing from Enterprise Singapore. Request for permission can be sent to: standards@enterprisesg.gov.sg.

© ISO 2019 – All rights reserved
© Enterprise Singapore 2020

ISBN 978-981-48-9490-6

The content of this Singapore Standard was approved on 2 April 2020 by the Biomedical and Health Standards Committee (BHSC) under the purview of the Singapore Standards Council.

First published, 2020

BHSC consists of the following members:

	Name	Representation
Chairman	: Dr Yong Chern Chet	<i>Individual Capacity</i>
Deputy Chairmen	: Mr Vincent Cheung	<i>Individual Capacity</i>
	Ms Selina Seah	<i>Changi General Hospital</i>
	Ms Wong Woei Jiuang	<i>Health Sciences Authority</i>
Advisor	: Ms Jacqueline Monteiro	<i>Individual Capacity</i>
Secretary	: Mr Kevin Tan	<i>Singapore Manufacturing Federation – Standards Development Organisation</i>
Members	: Mr Alec Chow Boon Kuan	<i>Medtronic International Ltd</i>
	Mr Chung Kwong Yuew	<i>Temasek Polytechnic (BioMedical Engineering Faculty)</i>
	Ms Heidi Goh	<i>Singapore Manufacturing Federation (Medical Technology Industry Group)</i>
	Prof James Goh	<i>Biomedical Engineering Society (Singapore)</i>
	Dr Lai Choon Sheen	<i>Eu Yan Sang International Ltd</i>
	Dr Christopher Lam	<i>Health Sciences Authority</i>
	Assoc Prof Leo Hwa Liang	<i>National University of Singapore</i>
	Dr Lin Jianhua	<i>TÜV SÜD PSB Pte Ltd</i>
	Dr Leonard Loh	<i>Nanyang Polytechnic</i>
	Ms Audrey Lok	<i>Enterprise Singapore</i>
	Assoc Prof Eddie Ng Yin Kwee	<i>Nanyang Technological University</i>
	Dr Ong Siew Hwa	<i>Acumen Research Laboratories Pte Ltd</i>
	Dr Padmanabhan Saravanan	<i>Temasek Polytechnic (Centre of Innovation for Complementary Health Products)</i>
	Mr Peh Ruey Feng	<i>Individual Capacity</i>
	Prof Tan Puay Hoon	<i>Singapore Health Services Pte Ltd</i>
	Ms Wang Dan	<i>Biosensors International Group</i>
	Dr Sidney Yee	<i>Diagnostics Development Hub – Accelerate Technologies Pte Ltd</i>
	Dr Zhou Zhihong	<i>Singapore Bioimaging Consortium</i>

BHSC sets up the Technical Committee on Quality Management Systems to oversee the preparation of this standard. The Technical Committee consists of the following members:

	Name	Representation
Chairman	: Ms Heidi Goh	<i>Individual Capacity</i>
Secretary	: Mr Kevin Tan	<i>Singapore Manufacturing Federation – Standards Development Organisation</i>
Members	: Ms Jasmine Chan	<i>Konica Minolta Business Solutions Asia Pte Ltd</i>
	Ms Shiirlyn Ee	<i>Illumina</i>
	Ms Katherine Goh	<i>Singapore Accreditation Council</i>
	Dr Christopher Lam	<i>Health Sciences Authority</i>
	Mr Ng Chee Kai	<i>Becton Dickinson Medical Products Pte Ltd</i>
	Mr Su Jinyao	<i>Diagnostics Development Hub – Accelerate Technologies Pte Ltd</i>
	Mr Ariq Tan	<i>Sivantos</i>
	Ms Grace Tan	<i>Edward Lifesciences (Singapore) Pte Ltd</i>
	Ms Diana Teo	<i>Medtronic International Ltd</i>
	Ms Wang Dan	<i>Biosensors International Group</i>
	Ms Zhu Huifang	<i>Smith & Nephew</i>

The Technical Committee sets up the National Mirror Working Group on ISO/TC 210 to prepare this standard. The Working Group consists of the following experts who contribute in their *individual capacity*:

	Name
Convenor	: Dr Margam Chandrasekaran
Secretary	: Mr She Long Huai
Members	: Ms Heidi Goh
	Ms How Pei Sin
	Mr Liew Ee Bin
	Mr Jason Lim
	Mr Caleb Ng
	Mr Narayanan Sethu
	Mr Paul Tan

The organisations in which the experts of the National Mirror Working Group are involved are:

Access-2-Healthcare

BioPharmaspec UK Ltd

Edwards Lifesciences (Singapore) Pte Ltd

Sanmina Corporation Singapore

Singapore Manufacturing Federation (Medical Technology Industry Group)

Stendard

SYSTEMED Pte Ltd

TÜV SÜD PSB Pte Ltd

Wise Consultant and Services Pte Ltd

Contents

	Page
National Foreword.....	6
Foreword.....	7
Introduction.....	9
1 Scope.....	11
2 Normative references.....	11
3 Terms and definitions.....	11
4 General requirements for <i>risk management</i> system.....	18
4.1 <i>Risk management process</i>	18
4.2 Management responsibilities.....	19
4.3 Competence of personnel.....	20
4.4 <i>Risk management plan</i>	20
4.5 <i>Risk management file</i>	21
5 <i>Risk analysis</i>	21
5.1 <i>Risk analysis process</i>	21
5.2 <i>Intended use and reasonably foreseeable misuse</i>	22
5.3 Identification of characteristics related to <i>safety</i>	22
5.4 Identification of <i>hazards and hazardous situations</i>	23
5.5 <i>Risk estimation</i>	23
6 <i>Risk evaluation</i>	24
7 <i>Risk control</i>	24
7.1 <i>Risk control option analysis</i>	24
7.2 Implementation of <i>risk control</i> measures.....	25
7.3 <i>Residual risk</i> evaluation.....	25
7.4 <i>Benefit-risk</i> analysis.....	26
7.5 <i>Risks</i> arising from <i>risk control</i> measures.....	26
7.6 Completeness of <i>risk control</i>	26
8 Evaluation of overall <i>residual risk</i>	26
9 <i>Risk management</i> review.....	27
10 Production and <i>post-production</i> activities.....	27
10.1 General.....	27
10.2 Information collection.....	27
10.3 Information review.....	28
10.4 Actions.....	28
Annex A (informative) Rationale for requirements.....	30
Annex B (informative) <i>Risk management process</i> for <i>medical devices</i>	40
Annex C (informative) Fundamental <i>risk</i> concepts.....	44
Bibliography.....	51

National Foreword

This Singapore Standard was prepared by the National Mirror Working Group on ISO/TC 210 set up by the Technical Committee on Quality Management Systems under the purview of BHSC.

This Standard is identical with ISO 14971:2019, “Medical devices — Application of risk management to medical devices”, published by the International Organization for Standardization.

NOTE – Reference to International Standards are replaced by applicable Singapore Standards/Technical References.

Attention is drawn to the possibility that some of the elements of this Singapore Standard may be the subject of patent rights. Enterprise Singapore shall not be held responsible for identifying any or all of such patent rights.

NOTE

- 1. Singapore Standards (SSs) and Technical References (TRs) are reviewed periodically to keep abreast of technical changes, technological developments and industry practices. The changes are documented through the issue of either amendments or revisions. Where SSs are deemed to be stable, i.e. no foreseeable changes in them, they will be classified as “Mature Standards”. Mature Standards will not be subject to further review, unless there are requests to review such standards.*
- 2. An SS or TR is voluntary in nature except when it is made mandatory by a regulatory authority. It can also be cited in contracts making its application a business necessity. Users are advised to assess and determine whether the SS or TR is suitable for their intended use or purpose. If required, they should refer to the relevant professionals or experts for advice on the use of the document. Enterprise Singapore and the Singapore Standards Council shall not be liable for any damages whether directly or indirectly suffered by anyone or any organisation as a result of the use of any SS or TR. Although care has been taken to draft this standard, users are also advised to ensure that they apply the information after due diligence.*
- 3. Compliance with a SS or TR does not exempt users from any legal obligations.*

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 210, *Quality management and corresponding general aspects for medical devices*, and IEC/SC 62A, *Common aspects of electrical equipment used in medical practice*.

This third edition cancels and replaces the second edition (ISO 14971:2007), which has been technically revised. The main changes compared to the previous edition are as follows:

- A clause on normative references has been included, in order to respect the requirements for fixed in Clause 15 of ISO/IEC Directives, Part 2:2018.
- The defined terms are updated and many are derived from ISO/IEC Guide 63:2019. Defined terms are printed in italic to assist the reader in identifying them in the body of the document.
- Definitions of *benefit*, *reasonably foreseeable misuse* and *state of the art* have been introduced.
- More attention is given to the *benefits* that are expected from the use of the *medical device*. The term *benefit-risk* analysis has been aligned with terminology used in some regulations.
- It is explained that the *process* described in ISO 14971 can be used for managing *risks* associated with *medical devices*, including those related to data and systems security.
- The method for the evaluation of the overall *residual risk* and the criteria for its acceptability are required to be defined in the *risk management* plan. The method can include gathering

and reviewing data and literature for the *medical device* and for similar *medical devices* and similar other products on the market. The criteria for the acceptability of the overall *residual risk* can be different from the criteria for acceptability of individual *risks*.

- The requirements to disclose *residual risks* have been moved and merged into one requirement, after the overall *residual risk* has been evaluated and judged acceptable.
- The review before commercial distribution of the *medical device* concerns the execution of the *risk management* plan. The results of the review are documented as the *risk management* report.
- The requirements for production and *post-production* activities have been clarified and restructured. More detail is given on the information to be collected and the actions to be taken when the collected information has been reviewed and determined to be relevant to *safety*.
- Several informative annexes are moved to the guidance in ISO/TR 24971, which has been revised in parallel. More information and a rationale for the requirements in this third edition of ISO 14971 have been provided in Annex A. The correspondence between the clauses of the second edition and those of this third edition is given in Annex B.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

The requirements contained in this document provide *manufacturers* with a framework within which experience, insight and judgment are applied systematically to manage the *risks* associated with the use of *medical devices*.

This document was developed specifically for *manufacturers* of *medical devices* on the basis of established principles of *risk management* that have evolved over many years. This document could be used as guidance in developing and maintaining a *risk management process* for other products that are not necessarily *medical devices* in some jurisdictions and for suppliers and other parties involved in the *medical device life cycle*.

This document deals with *processes* for managing *risks* associated with *medical devices*. *Risks* can be related to injury, not only to the patient, but also to the user and other persons. *Risks* can also be related to damage to property (for example objects, data, other equipment) or the environment.

Risk management is a complex subject because each stakeholder can place a different value on the acceptability of *risks* in relation to the anticipated *benefits*. The concepts of *risk management* are particularly important in relation to *medical devices* because of the variety of stakeholders including medical practitioners, the organizations providing health care, governments, industry, patients and members of the public.

It is generally accepted that the concept of *risk* has two key components:

- the probability of occurrence of *harm*; and
- the consequences of that *harm*, that is, how severe it might be.

All stakeholders need to understand that the use of a *medical device* involves an inherent degree of *risk*, even after the *risks* have been reduced to an acceptable level. It is well known that in the context of a clinical *procedure* some *residual risks* remain. The acceptability of a *risk* to a stakeholder is influenced by the key components listed above and by the stakeholder's perception of the *risk* and the *benefit*. Each stakeholder's perception can vary depending upon their cultural background, the socio-economic and educational background of the society concerned and the actual and perceived state of health of the patient. The way a *risk* is perceived also takes into account other factors, for example, whether exposure to the *hazard* or *hazardous situation* seems to be involuntary, avoidable, from a man-made source, due to negligence, arising from a poorly understood cause, or directed at a vulnerable group within society.

As one of the stakeholders, the *manufacturer* reduces *risks* and makes judgments relating to the *safety* of a *medical device*, including the acceptability of *residual risks*. The *manufacturer* takes into account the generally acknowledged *state of the art*, in order to determine the suitability of a *medical device* to be placed on the market for its *intended use*. This document specifies a *process* through which the *manufacturer* of a *medical device* can identify *hazards* associated with the *medical device*, estimate and evaluate the *risks* associated with these *hazards*, control these *risks*, and monitor the effectiveness of the controls throughout the *life cycle* of the *medical device*.

The decision to use a *medical device* in the context of a particular clinical *procedure* requires the *residual risks* to be balanced against the anticipated *benefits* of the *procedure*. Such decisions are beyond the scope of this document and take into account the *intended use*, the circumstances of use, the performance and *risks* associated with the *medical device*, as well as the *risks* and *benefits* associated with the clinical *procedure*. Some of these decisions can be made only by a qualified medical practitioner with knowledge of the state of health of an individual patient or the patient's own opinion.

For any particular *medical device*, other standards or regulations could require the application of specific methods for managing *risk*. In those cases, it is necessary to also follow the requirements outlined in those documents.

The verbal forms used in this document conform to the usage described in Clause 7 of the ISO/IEC Directives, Part 2:2018. For the purposes of this document, the auxiliary verb:

- “shall” means that compliance with a requirement or a test is mandatory for compliance with this document;
- “should” means that compliance with a requirement or a test is recommended but is not mandatory for compliance with this document;
- “may” is used to describe permission (e.g. a permissible way to achieve compliance with a requirement or test);
- “can” is used to express possibility and capability; and
- “must” is used to express an external constraint that is not a requirement of the document.

Medical devices — Application of risk management to medical devices

1 Scope

This document specifies terminology, principles and a *process* for *risk management of medical devices*, including software as a *medical device* and *in vitro diagnostic medical devices*. The *process* described in this document intends to assist *manufacturers of medical devices* to identify the *hazards* associated with the *medical device*, to estimate and evaluate the associated *risks*, to control these *risks*, and to monitor the effectiveness of the controls.

The requirements of this document are applicable to all phases of the *life cycle* of a *medical device*. The *process* described in this document applies to *risks* associated with a *medical device*, such as *risks* related to biocompatibility, data and systems security, electricity, moving parts, radiation, and usability.

The *process* described in this document can also be applied to products that are not necessarily *medical devices* in some jurisdictions and can also be used by others involved in the *medical device life cycle*.

This document does not apply to:

- decisions on the use of a *medical device* in the context of any particular clinical *procedure*; or
- business *risk management*.

This document requires *manufacturers* to establish objective criteria for *risk* acceptability but does not specify acceptable *risk* levels.

Risk management can be an integral part of a quality management system. However, this document does not require the *manufacturer* to have a quality management system in place.

NOTE Guidance on the application of this document can be found in ISO/TR 24971^[9].

2 Normative references

There are no normative references in this document.